AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2016

Jun 10, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2016-06-08

Reporting Person: Biller Scott (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-08	Common stock	M	22306	$0.4675	Acquired	81376	Direct
2016-06-08	Common stock	M	5194	$31.64	Acquired	86570	Direct
2016-06-08	Common stock	S	27500	$65.00	Disposed	59070	Direct
2016-06-10	Common stock	M	15200	$0.4675	Acquired	74270	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-08	Stock option (right to buy)	$0.4675	M	22306	Disposed	2020-12-06	Common stock (22306)	Direct
2016-06-08	Stock option (right to buy)	$31.64	M	5194	Disposed	2024-03-04	Common stock (5194)	Direct
2016-06-10	Stock option (right to buy)	$0.4675	M	15200	Disposed	2020-12-06	Common stock (15200)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: This option was granted on December 7, 2010. The shares underlying this option vest as to 25% of the shares on September 20, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F4: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.